High Risk, Low Prevalence: Acute Chest Syndrome

Acute chest syndrome is a high-mortality acute lung injury in sickle cell disease, and a normal initial chest x-ray does not exclude it. Early recognition hinges on new respiratory symptoms plus a new radiodensity somewhere on imaging, with lung ultrasound or CT stepping in when suspicion stays high.

Recognizing Acute Chest Syndrome

• High mortality phenotype: Acute chest syndrome causes about 25% of deaths in sickle cell disease, and each episode carries roughly 9% mortality, making even subtle early presentations worth treating aggressively.
• Core diagnostic frame: Think ACS when fever or new respiratory symptoms in sickle cell disease are paired with a new segmental radiodensity on imaging, often alongside vaso-occlusive pain crisis.
• False-negative chest x-ray: A negative initial x-ray does not rule out ACS because consolidation commonly lags behind the clinical picture; we get into when ultrasound or CT should move up in the episode.
• Typical trigger patterns: Nearly half of cases have no identifiable trigger, but vaso-occlusive pain crisis is the leading adult precipitant while asthma is a common pediatric driver.
• Clues to severe disease: Multilobar involvement, neurologic symptoms, worsening hypoxemia, and rapid progression toward multiorgan injury should raise concern for the severe ACS phenotype.

ED Evaluation And Initial Management

• Pulse oximetry limitations: Standard pulse oximetry is less reliable in sickle cell disease and may miss alveolar hypoxemia; if the patient looks worse than the sat suggests, get an ABG with co-oximetry.
• Imaging beyond radiography: Lung ultrasound performs well in ACS, with reported sensitivity up to 88-100%, and key findings include B-lines, consolidation, and pleural effusion.
• Universal antibiotic coverage: All patients with ACS should receive antibiotics because infection triggers about 25% of cases, and atypical coverage belongs in every regimen.
• Supportive care priorities: Analgesia, incentive spirometry, bronchodilators for wheezing, and careful euvolemia are the backbone of treatment, with fluid overload avoided because it can worsen pulmonary edema.
• Escalating respiratory support: HFNC or NIPPV can recruit alveoli and reduce the chance of intubation, while invasive ventilation follows standard airway, oxygenation, or ventilation failure criteria.
• Transfusion strategy decisions: Simple transfusion improves oxygen-carrying capacity, while exchange transfusion lowers the HbS burden for severe or rapidly progressive disease. We walk through the bedside decision points in the chapter.

Severe Phenotypes And Important Overlap

• Rapidly progressive ACS: A distinct high-risk phenotype can progress to respiratory failure within 24 hours and may bring AKI, hepatic dysfunction, altered mental status, or broader multiorgan failure.
• Predictors of severity: Fever, oxygen saturation under 95%, asthma history, leukocytosis, asplenia, lower baseline hemoglobin, and platelets under 200,000 all point toward a rougher course.
• Pulmonary embolism overlap: Pulmonary embolism can be the trigger or a concurrent diagnosis in ACS, especially when there is no clear precipitant or the presentation seems out of proportion to the imaging.
• COVID-associated ACS: COVID-19 raises the risk of pneumonia, pain, and ACS in sickle cell disease, and hypoxic patients should still receive steroids despite rebound vaso-occlusive concerns.

References:

1. Koehl JL, Koyfman A, Hayes BD, Long B. High risk and low prevalence diseases: Acute chest syndrome in sickle cell disease. Am J Emerg Med. 2022 Aug;58:235-244. Epub 2022 Jun 11. PMID: 35717760.
2. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group [published correction appears in N Engl J Med 2000 Sep 14;343(11):824]. N Engl J Med. 2000;342(25):1855-1865. PMID: 10861320
3. Spring J, Munshi L. Hematology Emergencies in Critically Ill Adults: Benign Hematology. Chest. 2022;161(5):1285-1296.  PMID:35007552
4. Chaturvedi S, Ghafuri DL, Glassberg J, Kassim AA, Rodeghier M, DeBaun MR. Rapidly progressive acute chest syndrome in individuals with sickle cell anemia: a distinct acute chest syndrome phenotype. Am J Hematol. 2016;91(12):1185-1190. PMID:27543812
5. National Heart, Lung, and Blood Institute. Clinical Guide for the Management of Sickle Cell Disease, 2002. https://www.nhlbi.nih.gov/resources/management-sickle-cell-disease. Published January 2002.
6. Howard J, Hart N, Roberts-Harewood M, et al. Guideline on the management of acute chest syndrome in sickle cell disease. Br J Haematol. 2015;169(4):492-505. PMID: 25824256
7. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327-355. PMID:31985807 
8. Alkindi S, Al-Busaidi I, Al-Salami B, Raniga S, Pathare A, Ballas SK. Predictors of impending acute chest syndrome in patients with sickle cell anaemia. Sci Rep. 2020;10(1):2470. Published 2020 Feb 12. PMID: 32051480
9. Morris C, Vichinsky E, Styles L. Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough?. Ann Emerg Med. 1999;34(1):64-69. PMID: 10381996